Publié le Un commentaire

Oral Microbiome Associated with Cognitive Performance

An analysis of oral microbes in older adults has indicated an association between microbial diversity and executive function performance [1].

Multiple factors impact cognitive impairment risk

Aging is one of the major risk factors for cognitive impairment and dementia, but it is not the only one. According to multiple research papers, the risk of developing cognitive impairment and dementia is impacted by factors such as lower educational level; toxin exposure; physical inactivity; systemic inflammation; comorbidities such as diabetes, cardiovascular disease, and stroke; and gut dysbiosis: the perturbed composition of gut microbes [2, 3, 4, 5].

While the gut microbiome is well studied, microbes in the oral cavity get less attention. However, some studies suggest a connection between oral cavity dysbiosis and neurodegenerative disorders. This prompted the researchers to test the association between the oral microbiome and Alzheimer’s disease in small-scale clinical studies. The results of those studies do not give a clear answer, since some of the studies report a connection while others don’t see it [6, 7].

In this study, the researchers aimed to build on that knowledge and address a similar question: whether “the oral microbiome is associated with cognitive function measurements” in older adults.

They used data from the National Health and Nutrition Examination Survey (NHANES) 2011-2012, a study conducted by the U.S. Centers for Disease Control and Prevention (CDC). For their analysis, the authors used data from 605 adults between 60 and 69 years old.

Microbes and cognitive function

During the initial analysis, the researchers observed significantly lower scores for all the cognitive tests performed in the older participants with lower educational levels, lower income, current smoking, lower physical activity, and pre-existing diabetes and hypertension.

More in-depth analysis looked at microbiome α- and β-diversity. α-diversity indicates microbiome diversity within a given sample, and β-diversity compares diversity between samples. The analysis revealed a significant positive association between α-diversity and the Digit Symbol Substitution Test (DSST), which measures brain health based on executive function and processing speed. The author’s models pointed out that “higher α-diversity was significantly associated with higher odds of better cognitive function based on DSST.” The results also suggested the importance of β-diversity for DSST.

However, other cognitive domains didn’t show significant associations with α- and β-diversity. Taken together, these resultst suggest that oral dysbiosis has an impact on executive function as tested with DSST, but there was no significant impact on verbal memory as tested with other cognitive tests.

The models also identified the association between the oral microbiome and subjective memory changes. Specifically, higher levels of α-diversity in participants were associated with a lower possibility of experiencing subjective memory changes, and participants who experienced subjective memory changes had significantly different β-diversity than those who didn’t experience them.

The authors discuss that their results are mostly consistent with similar observations by other researchers. If differences arise, they can be caused by different methods of obtaining samples or small cohorts in some studies that were insufficient for proper statistical analysis.

Potential role of inflammation

The authors elaborate on the potential mechanisms underlying the connection between oral microbial dysbiosis and cognitive function impairment. Based on previous research, they hypothesize the role of inflammation in this process, as, for example, other researchers found higher concentrations of inflammatory markers in plasma or cerebrospinal fluid in patients with mild cognitive impairment compared to normal individuals [8].

They also suggest that changes to the oral microbiome can be a potential source of low-grade systemic inflammation, which might play a role in cognitive impairment and dementia development. They give an example of a periodontal disease associated with oral microbial dysbiosis and increased pro-inflammatory mediators.

Large dataset with some limitations

The large dataset used in this study was one of its major strengths compared to smaller studies. Additionally, the availability of other information describing this cohort allowed for adjustment for extensive covariates. However, like every study, this one suffers from some limitations, including the inability to infer causality, which means that the results of this study cannot tell “whether cognitive impairment occurred before or after oral dysbiosis or whether declining health itself influenced both cognitive function and the oral microbial community.”

Since the data of specific microbial species is unavailable in NHANES, that limites the analysis. The generalizability of the results is also limited to this study’s particular age group. The authors also mention that their choice of statistical analysis (not correcting for a number of comparisons) increases the risk of false positives.

In this cross-sectional analysis using data from the NHANES 2011–2012, we found that the α-diversity of the oral microbiome was significantly associated with DSST among U.S. older adults aged 60–69 years after controlling for potential confounding variables. Moreover, cognitive function status based on DSST was associated with distinct oral microbial compositions. Similar results were also identified in the association between the oral microbiome and subjective memory changes. Our study highlights the potential contribution of the oral microbiome to the maintenance of normal cognitive function.

To do this, we need your support. Your charitable contribution tranforms into rejuvenation research, news, shows, and more. Will you help?

Literature

[1] Lin, T. Y., Wang, P. Y., Lin, C. Y., & Hung, S. C. (2024). Association of the oral microbiome with cognitive function among older adults: NHANES 2011-2012. The journal of nutrition, health & aging, 28(8), 100264. Advance online publication.

[2] Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., Costafreda, S. G., Dias, A., Fox, N., Gitlin, L. N., Howard, R., Kales, H. C., Kivimäki, M., Larson, E. B., Ogunniyi, A., Orgeta, V., … Mukadam, N. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet (London, England), 396(10248), 413–446.

[3] Kipinoinen, T., Toppala, S., Rinne, J. O., Viitanen, M. H., Jula, A. M., & Ekblad, L. L. (2022). Association of Midlife Inflammatory Markers With Cognitive Performance at 10-Year Follow-up. Neurology, 99(20), e2294–e2302.

[4] Seo, D. O., & Holtzman, D. M. (2020). Gut Microbiota: From the Forgotten Organ to a Potential Key Player in the Pathology of Alzheimer’s Disease. The journals of gerontology. Series A, Biological sciences and medical sciences, 75(7), 1232–1241.

[5] Meyer, K., Lulla, A., Debroy, K., Shikany, J. M., Yaffe, K., Meirelles, O., & Launer, L. J. (2022). Association of the Gut Microbiota With Cognitive Function in Midlife. JAMA network open, 5(2), e2143941.

[6] Wu, Y. F., Lee, W. F., Salamanca, E., Yao, W. L., Su, J. N., Wang, S. Y., Hu, C. J., & Chang, W. J. (2021). Oral Microbiota Changes in Elderly Patients, an Indicator of Alzheimer’s Disease. International journal of environmental research and public health, 18(8), 4211.

[7] Cirstea, M. S., Kliger, D., MacLellan, A. D., Yu, A. C., Langlois, J., Fan, M., Boroomand, S., Kharazyan, F., Hsiung, R. G. Y., MacVicar, B. A., Chertkow, H., Whitehead, V., Brett Finlay, B., & Appel-Cresswell, S. (2022). The Oral and Fecal Microbiota in a Canadian Cohort of Alzheimer’s Disease. Journal of Alzheimer’s disease : JAD, 87(1), 247–258.

[8] Shen, X. N., Niu, L. D., Wang, Y. J., Cao, X. P., Liu, Q., Tan, L., Zhang, C., & Yu, J. T. (2019). Inflammatory markers in Alzheimer’s disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies. Journal of neurology, neurosurgery, and psychiatry, 90(5), 590–598.

Publié le Laisser un commentaire

Longevity and DeSci Recap – May 2024

In this latest edition of the Longevity and DeSci Recap, we’ll take a look back at May’s events, research, and investments to give you the latest update on what’s going on in the Longevity and DeSci world.

As the weather is heating up, so too are events surrounding longevity. Not only are there four great conferences coming up in the next few months, but organizations across the globe are securing funding, producing research, and getting results.

Upcoming conferences and events

Longevity event of the year in Dublin

Enthusiasts from all over the world will jet to an emerald isle for the most anticipated event of the season: Longevity Summit Dublin 2024. With the conference just days away, there’s still time to scoop up a ticket and join talks on rejuvenation biotechnology and longevity. This year’s speakers include Luisa G Bâcă from the National Institute on Aging, David Barzilai, founder and CEO of Healthspan Coaching LLC, Laurence Ion of VitaDAO, Brian Kennedy of the Centre for Healthy Longevity and Professor Departments of Biochemistry and Physiology at National University of Singapore, and Manuel Serrano of Altos Labs, among many others.

11th Aging Research and Drug Discovery Meeting

Returning to the stage this August, the 11th ARDD conference will host industry experts such as Nir Barzilai, Vera Gorbunova, and Aubrey de Grey in an exciting longevity conference. Tickets and event details are available here. The event promises to dive into topics including senolytics, stem cell research, healthy longevity, and epigenetic reprogramming.

HLTH around the world

This June 17-20th in Amsterdam, HLTH will host its European conference with renowned speakers covering a variety of health-related topics. Then it’s on to October, when HLTH will move its focus to the Las Vegas stage, covering everything from AI to nutrition to aging.

Longevity Investors Conference

Gstaad, Switzerland is the place to be for longevity investors this September. Between the 24th and 27th of that month, top-level longevity investors will gather together among the mountains to discuss the hottest longevity topics this year. People who wish to attend the exclusive event must pass a screening before being able to purchase tickets. Apply here to attend.

Tech breakthroughs & new research

Female-led biotech announces new innovative fertility research

Gameto, a biotech company focused on women’s health, recently announced novel research into cellular engineering and manufacturing techniques behind its proprietary solution Fertilo. This study looks into how ovarian support cells enhance in vitro fertilization (IVF) outcomes in an effort to improve further understanding of fertility issues.

AI heart care is here

This May, Caristo Diagnostics published a study in The Lancet on inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease. What makes this study unique is that it draws on AI technology to assess cardiac risk utilizing its CaRi-Heart® technology, which the company claims can predict cardiac events due to coronary inflammation up to 10 years in advance. This could be a game-changer for heart care.

Innovative liver treatment on the horizon?

Immorta Bio Inc, a longevity company, announced its positive results with a new liver treatment using PMSC-11 stem cell therapy. The proprietary technology behind the solution resulted in a significant suppression of liver damage in a carbon tetrachloride model, preserving albumin production and preventing spikes in liver enzymes. Due to these results, the company is now seeking further preclinical trials before proceeding to FDA approval for clinical trials.

Longevity investment news

Mitochondrial research organization raises additional $12.5 million in funding

Lucy Therapeutics, a biotech startup focused on longevity through mitochondrial research, has secured $12.5 million in funding to support its drug discovery programs. The company’s current research is centered on targeting Alzheimer’s, Parkinson’s, and Rett syndrome in a novel way. This funding round was led by Engine Ventures and Safar Partners, with new contributions from the illustrious Bill Gates, Parkinson’s UK, and the Michael J. Fox Foundation.

Stealth mode off, development mode on

Radar Therapeutics is definitely on the radar this month, as it’s emerged from stealth mode with $13.4 million in tow. This biotech startup from Berkeley, California isn’t just about the money; rather, it’s bringing the scientific goods too. Radar Therapeutics leverages advanced mRNA technology and proprietary regulatory control elements to create precision therapeutics that can address key challenges in genetic medicine, particularly in the longevity field. This latest funding will go toward this aim and help further this company’s research.

DAOs and communities

VitaRNA by Artan Bio is ongoing right now

VitaDAO, a biotech decentralized autonomous organization, is currently in the process of tokenizing the Artan Bio IP-NFT, an innovative way to fund research projects through an intellectual property NFT. With the aim of raising $300,000 in capital, this process is open to the public until June 6th.

Gitcoin’s DeSci round wraps

With a pool of 25,000 USDC, Gitcoin’s DeSci round ran from May 8th-23rd. Comprising 23 projects spanning a variety of domains, Just DNA-Seq took home the highest amount at $6517.11. The organization focused on an open-source genomics platform that helps people sequence the DNA of their loved ones to get insights into their genetic code. With a new round of funding to be announced, this is one to watch.

Vitalia summer program announced

What could be better than sun, sand, and longevity? At Vitalia in Roatan, Honduras, people who are looking for all these things this summer are welcome to join in the latest in a series of longevity city events. Spanning July 1st-31st, participants can partake in a unique program covering such things as a bio-acc summit, human augmentation week, and a startup investor demo day. Find out more about the event here.

Other DeSci and longevity news

Berlin’s Rejuvenation Startup Summit

This month saw the long-awaited Rejuvenation Startup Summit held in Berlin. Hosted by Michael Greve’s Forever Healthy Foundation, the event saw a number of exciting talks and networking opportunities for people interested in the longevity biotech field. Hevolution’s CEO Mehmood Khan took the keynote speech, highlighting the financial challenges posed by an aging population, and how diverse approaches, such as Rockfish’s novel senolytics pathway and NaNotics’ innovative nanoparticle platform, could be part of the solution.

Lifespan.io Executive Director Stephanie Dainow also took the stage, speaking about the recent merger of Lifespan.io and the SENS Research Foundation, detailing how our shared mission plans to advance longevity. Get a closer look at all the details here.

Longevity now on your phone

Novos, a tech company focused on longevity, has just launched an AI-backed app for improving longevity. The app helps users discover their biological age and take daily actions to improve it. Find out more here.

The season of collaboration

Just as Lifespan.io announced its merger with SENS Research Foundation, 2024 is proving to be the year of working together for a common goal. QuantaIX Neuroscience has joined forces with The Sheba Longevity Center to develop new technologies in the world of brain health diagnostics. Aiming to address the needs of the aging population, the teams will look into predictive analytics, early detection and intervention strategies to improve human healthspan.

Social media pages to follow this month

Gitcoin — For people interested in the crypto side of the coin, Gitcoin’s social media follows the process of the company’s efforts in empowering communities to fund, build and protect what matters.

DeSci Berlin — Follow up on one of the most exciting conferences of the year and find out all the latest about next year’s event.

Laurence Ion (VitaDAO) — Follow the latest happenings at VitaDAO and related DeSci projects from one of the organization’s key figures.

Publié le Laisser un commentaire

Estrogen Metabolite Robustly Increases Lifespan in Male Mice

In the newest study by the Interventions Testing Program, 16α-hydroxyestriol and canagliflozin significantly increased lifespan in male mice but were deleterious for females [1].

The golden standard

The Interventions Testing Program, now entering its 20th year, is a monumental undertaking by the National Institute on Aging aimed at rigorously testing compounds for their possible effects on lifespan in mice. The ITP is considered the golden standard of mouse longevity studies for a reason. It is run in three academic facilities simultaneously, on large cohorts of genetically heterogeneous, naturally aging mice that are kept in identical conditions.

ITP’s stamp of approval on a molecule is a big deal. Currently, the absolute champion is a combination of rapamycin and the anti-diabetes drug acarbose, which produced a 28% increase in median lifespan in females and a 34% increase in males [2].

From 2004 to 2023, the ITP tested dozens of compounds and published 77 research papers. The previous one highlighted the first supplement in the program’s history to produce significant life extension: astaxanthin.

Good for males, bad for females

Now, the newest ITP paper is out, so brace yourself for the results. In this latest cohort, the researchers tested several molecules: alpha-ketoglutarate (AKG), 2,4-dinitrophenol (DNP), hydralazine, nebivolol, 16α-hydroxyestriol, and sodium thiosulfate. Additionally, it evaluated the effects of canagliflozin, which already produced significant life extension in one of the previous cohorts when administered late in life.

16α-hydroxyestriol was the star of this study, producing a 15% increase in median lifespan in male mice. However, it lowered median lifespan in females by 7%. While many drugs affect lifespan sex-specifically, opposing effects are rare; in fact, this is the first case in ITP’s history. Interestingly, we have another example from the same study: canagliflozin, when started at 16 months of age, led to a 14% increase in median lifespan in males and a 6% decline in females. In a previous ITP study, when started at 6 months, canagliflozin increased male lifespan without affecting female lifespan. All other tested drugs did not have a statistically significant effect on lifespan in either sex.

The winners…

16α-hydroxyestriol is a metabolite of estrogen. Its inclusion in the study was due to the previous success of 17-α-estradiol, also called “the non-feminizing estrogen”, which increased median survival by 20% in males only [3]. The researchers hypothesized that 16α-hydroxyestriol might produce a similar lifespan extension in both sexes, but they were harshly proved wrong. The authors do not know what caused the significant reduction in female lifespan.

While estrogen supplementation might be beneficial for aging males, understanding the exact mechanisms and perfecting a therapy will take some time. 16α-hydroxyestriol is only the seventh ITP-tested drug to induce at least a 10% lifespan increase in one or both sexes.

Canagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor and is used to treat type 2 diabetes. Blocking SGLT2 in the kidneys reduces the reabsorption of glucose back into the blood and helps to lower blood sugar levels. Interestingly, the more famous anti-diabetes drug metformin failed to produce significant life extension [4].

Female mice had a much higher concentration of canagliflozin in the blood than males. The researchers speculate that “hypothetical benefits (of canagliflozin) that might accrue in females at younger ages are then countered by harmful effects at ages above 16 months, when blood levels of this drug are particularly high in females.” They plan a series of new experiments hoping to avoid this late-life toxic effect. Still, the success of a mid-life canagliflozin treatment in males is a great result. With this study, canagliflozin has become the fourth ITP-tested drug to increase lifespan when started later in life.

…and the losers

The most high-profile failure was AKG, which has been touted as a potential geroprotector. AKG is involved in energy production in cells, and some research suggests that its supplementation can improve cellular function and reduce oxidative stress. “Our data on AKG,” the researchers wrote, “fail to confirm the published work in which this agent produced a small but significant lifespan benefit in female C57BL/6 mice” (those mice, widely known as B6, are inbred, as opposed to the genetically heterogenous mice used in the ITP). AKG is being tested by the ITP in another cohort, starting at an earlier age.

Sodium thiosulfate, a sulfur donor used as an antidote for cyanide poisoning, produced a 5% increase in median lifespan in males but not in females. This result fell just short of statistical significance, but the researchers haven’t given up on this inorganic molecule and plan to try other doses.

To do this, we need your support. Your charitable contribution tranforms into rejuvenation research, news, shows, and more. Will you help?

Literature

[1] Miller, R. A., Harrison, D. E., Cortopassi, G. A., Dehghan, I., Fernandez, E., Garratt, M., … & Strong, R. (2024). Lifespan effects in male UM-HET3 mice treated with sodium thiosulfate, 16-hydroxyestriol, and late-start canagliflozin. GeroScience, 1-14.

[2] Strong, R., Miller, R. A., Cheng, C. J., Nelson, J. F., Gelfond, J., Allani, S. K., … & Harrison, D. E. (2022). Lifespan benefits for the combination of rapamycin plus acarbose and for captopril in genetically heterogeneous mice. Aging Cell, 21(12), e13724.

[3] Harrison, D. E., Strong, R., Allison, D. B., Ames, B. N., Astle, C. M., Atamna, H., … & Miller, R. A. (2014). Acarbose, 17‐α‐estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging cell, 13(2), 273-282.

[4] Strong, R., Miller, R. A., Antebi, A., Astle, C. M., Bogue, M., Denzel, M. S., … & Harrison, D. E. (2016). Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer. Aging cell, 15(5), 872-884.